MétaCan
Menu
Back to cohort
Record W4402348936 · doi:10.1093/jnci/djae209

The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairment

2024· article· en· W4402348936 on OpenAlexaff
Michelle C. Janelsins, Kathleen Van Dyk, Sheri J. Hartman, Thuy T. Koll, Christina K. Cramer, Glenn J. Lesser, Debra L. Barton, Karen M. Mustian, Lynne I. Wagner, Patricia A. Ganz, Peter D. Cole, Alexis Bakos, James C. Root, Kristina K. Hardy, Allison Magnuson, Robert J. Ferguson, Brenna C. McDonald, Andrew J. Saykin, Brian D. Gonzalez, Jeffrey S. Wefel, David A. Morilak, Saurabh Dahiya, Cobi J. Heijnen, Yvette P. Conley, Alicia K. Morgans, Donald Mabbott, Michelle Monje, Stephen R. Rapp, Vinai Gondi, Catherine Bender, Leanne Embry, Worta McCaskill‐Stevens, Judith O. Hopkins, Diane St. Germain, Susan G. Dorsey

Bibliographic record

VenueJNCI Journal of the National Cancer Institute · 2024
Typearticle
Languageen
FieldMedicine
TopicCancer-related cognitive impairment studies
Canadian institutionsHospital for Sick Children
FundersNational Cancer InstituteNational Institute on AgingNational Institutes of HealthU.S. Department of Health and Human Services
KeywordsObservational studyPsychological interventionClinical trialIntervention (counseling)MedicineCognitionQuality of life (healthcare)DiseaseInclusion (mineral)CancerRandomized controlled trialGerontologyPsychologyPsychiatryNursingInternal medicine

Abstract

fetched live from OpenAlex

Cancer-related cognitive impairment is a broad term encompassing subtle cognitive problems to more severe impairment. The severity of this impairment is influenced by host, disease, and treatment factors, and the impairment affects patients before, during, and following cancer treatment. The National Cancer Institute (NCI) Symptom Management and Health-Related Quality of Life Steering Committee (SxQoL SC) convened a clinical trial planning meeting to review the state of the science on cancer-related cognitive impairment and develop phase II/III intervention trials aimed at improving cognitive function in cancer survivors with non-central nervous system disease and longitudinal studies to understand the trajectory of cognitive impairment and contributing factors. Participants included experts in the field of cancer-related cognitive impairment, members of the SxQoL SC, patient advocates, representatives from all 7 NCI Community Oncology Research Program research bases, and the NCI. Presentations focused on the following topics: measurement, lessons learned from pediatric and geriatric oncology, biomarker and mechanism endpoints, longitudinal study designs, and pharmacological and behavioral intervention trials. Panel discussions provided guidance on priority cognitive assessments, considerations for remote assessments, inclusion of relevant biomarkers, and strategies for ensuring broad inclusion criteria. Three clinical trial planning meeting working groups (longitudinal studies as well as pharmacological and behavioral intervention trials) convened for 1 year to discuss and report on top priorities and to design studies. The meeting experts concluded that sufficient data exist to advance phase II/III trials using selected pharmacological and behavioral interventions for the treatment of cancer-related cognitive impairment in the non-central nervous system setting, with recommendations included herein.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.019
metaresearch head score (Gemma)0.020
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.339
Threshold uncertainty score0.989

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0190.020
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.001
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.436
GPT teacher head0.557
Teacher spread0.121 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations15
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueJNCI Journal of the National Cancer InstituteSame topicCancer-related cognitive impairment studiesFrench-language works237,207